ardiomyopathies are primary (i.e., genetic, mixed, or acquired) or secondary (e.g., infiltrative, toxic, inflammatory) and lead to progressive heart failure with significant morbidity and mortality.
ISSN 2287-0237 (online)/ 2287-9674 (print) NYHA = New York Heart Association, AICD = automatic implantable cardioverter defibrillator, CRTD = cardiac resynchronization therapy with defibrillator, NT-ProBNP = NT-ProB-type natriuretic peptide Stem cell treatment has gained popularity over the past 10 years because it offers a new treatment for end-stage or degenerative diseases such as heart failure, diabetes and spinal infarction. The stem cells used may vary from embryonic stem cell, fetal stem cell to adult stem cell. Embryonic and fetal stem cells are limited to clinical usages due to obvious ethical reasons and the potential for tumor growth in recipients. The induced pluripotent stem cell was newly developed and has great potentials. In cardiology, cardiac resident stem cells are promising. However, stem cells most commonly used in heart failure clinical trials were skeletal myoblasts and hematopoietic stem cells. Skeletal myoblast cells were the first type used; however skeletal myoblasts injection showed no LVEF improvement compared with controls in the randomized placebo-controlled myoblast autologous grafting in ICM patients (MAGIC trial):
3 skeletal myoblast cells were unable to integrate and synchronously contract with the host cardiomyocytes post-implantation. 4 The angiogenic cell precursors (ACPs) used in this study were generated from autologous peripheral blood and represent a heterogenic stem/ progenitor cell population of hematopoietic cells that potentially differentiates in vivo in response to tissue signals at injection site and lineage specific angiogenic precursors. 5 Animal experiments demonstrated these cells' efficacy; a significant reduction of myocardial scarring and increased blood vessel density in the direct intramyocardial injected areas. 6 We previously reported the feasibility and safety of using ACPs to treat cardiomyopathy. 7 Here we aim to report midterm results and assess clinical markers which can predict outcomes of intramyocardial ACPs injection for cardiomyopathy.
Materials and methods

Patient population
Between May 2005 and April 2010, 143 consecutive cardiomyopathy patients gave informed consent and underwent intramyocardial ACPs injection. Sixty patients were dilated cardiomyopathy (DCM) and 83 were ischemic cardiomyopathy (ICM). The study was approved by the Ethics Committee and Institutional Review Board. Screening of severe contagious infections, HIV and hepatitis were done; only patients testing negative were included in the study. Malignancy within the preceding 3 years was also an exclusion criterion. All patients had a recent coronary angiogram (within 6 months) confirming negative coronary artery disease status before the procedure. They all underwent pre-operative workups including routine chest x-ray, electrocardiography, and NT-ProB-type natriuretic peptide (NT-ProBNP). Echocardiography without stressing and/ or cardiac MRI (CMR) was performed in all cases. CMR was conducted using 3.0 Tesla MR Scanner (Achieva 3.0T systems with Philips Quasar Dual gradients, Philips Medical Systems, The Netherlands). Patients were excluded from the CMR study if they had contraindications such as metallic equipment implantation. They all undertook a six-minute walk test, New York Heart Association (NYHA) functional class evaluation and routine laboratory tests required for general anesthesia. Quality of life was evaluated at preoperative and postoperative periods with Short Form-36 (SF-36, a multi-purpose, short-form health survey). The SF-36 consists of 36 items or questions grouped into eight healthrelated aspects of the patient's life. The scores for each aspect can vary from 0-100; the higher the scores the better the quality of life. The score of 50 was considered normal. Patient's clinical characteristics are summarized in Table 1 
The cells
The adult stem cells used in this study are "Angiogenic Cell Precursors (ACPs)" developed by VesCell technology (VesCell™, TheraVitae Co. Ltd., Ness Ziona, Israel). 5 ACPs are derived from the patient's own blood, avoiding immunological concerns. Peripheral blood of 250 ml was collected from the patients and sent for cell expansion. Blood cultures for aerobic and anaerobic bacteria were also collected and confirmed negative results. Multipotent progenitor cells were isolated from the blood, rich in CD45, CD31 23 . The Limulus Amebocyte Lysate (LAL) test was performed on a sample of supernatant taken from the cell culture. Endotoxin levels below the acceptable limits were compulsory for the release of the final product. Gram stain was to assess bacterial contamination of tissue culture samples. Negative results of the Gram stain performed on samples taken from the washing medium of cells before vialing was compulsory for the release of the final product. Mycoplasma contamination was tested and a negative result of the test was also obtained. The product phenotype was assayed by immune staining, as well as for angiogenic potential (tube formation assay) and cytokine secretion. All cell preparations complied with pre-defined release criteria of safety and potency.
Immune Staining
Cell samples were washed in PBS and resuspended in 100 µl of PBS, stained with specific fluorochrome-conjugated anti-human antibodies or isotype-matched non-specific controls, and incubated in the dark for 30 minutes on ice. 
Tube Formation Assay
The angiogenesis potential of the cells was measured by their ability to form three-dimensional tube-like structures according to a widely-used scale using an in vitro angiogenesis assay kit (Chemicon) and scoring under an inverted light microscope (Nikon ECLIPSE TS-100).
Analysis of Cytokine Secretion
Samples of the harvested cells were washed in PBS and resuspended to one million in 1 ml X-vivo15 and grown for 24 hours in 24-well plates. Cytokine secretion in the supernatant was measured as compared to that of the medium only using flow cytometry and the BD™ CBA Human Angiogenesis Kit (Becton Dickinson).
Number of cells prior to injection was 46.2 ± 36.7 million (3.3-200) with 96.9 ± 3.5 % viability in DCM; number of cells prior to injection was 48.1 ± 37.0 million (1.6-165.6) with 96.4 ± 4.0 % viability in ICM. Cells were injected into all areas of the left ventricle in the DCM. For ICM, cells were injected into non-viable myocardium including interventricular septum and hypokinetic segments of the left ventricle.
Surgical Techniques
All DCM had intramyocardial cell injection alone by thoracoscopic technique or microthoracotomy. Most patients underwent microthoracotomy approach due to better exposure, control and shorter operative time. For ICM, 54 (65.1 %) had ACPs injection alone and 29 (34.9%) combined coronary artery bypass grafting (CABG) with ACPs injection.
Microthoracotomy for ACPs Injection
Under general anesthesia with one-lung ventilation, the patient was placed in the right lateral decubitus position. A 10-cm incision was made in the left chest at the 5 th intercostal space on the posterior axillary line. The chest cavity was examined and the pericardium was opened longitudinally anterior to the phrenic nerve. Pericardial traction stitches were
The Bangkok Medical Journal Vol. 13 Cells were injected with the 23-guage butterfly needle with home-made guard. The needle was brought to the heart and then the injections were done manually outside the chest with the extension line. There were 30 sites of injections, 0.5 ml/ injection. Cells were injected into non-viable myocardium predetermined by CMR or myocardial nuclear scan including interventricular septum and hypokinetic segments. After adequate hemostasis the microthoracotomy was closed with small chest drainage left in the 7 th intercostal space opening.
Off-Pump coronary artery bypass grafting (OPCAB)
OPCAB approach was carried out. After 1mg/kg of heparin was given, deep pericardial traction stitches were applied to verticalize the heart. The heart was then stabilized with an Octopus III or Octopus IV stabilizer (Medtronic, Inc., Minneapolis, MN 55432) without using any cardiac positioning device. Systemic systolic blood pressure in both groups was kept above 100 mmHg and central venous pressure/ pulmonary artery diastolic pressure in the 20's to maintain adequate perfusion. All operative maneuvers were routine.
Anastomoses was usually performed to the left anterior descending (LAD) and diagonal arteries first; or to the highest grade or totally obstructed arteries when the LAD system had less severe obstruction. After the measuring was completed the anastomosis was performed in the usual fashion using side to side anastomosis for sequential and end to side for distal end anastomosis with 4-8 interrupted stitches of 7-0 prolene. Intra-coronary shunt was used only in the large dominant right coronary artery or when patient was unstable or exhibited significant, persisting EKG changes after the occlusion. One right ventricular temporary epicardial pacing wire was inserted in these high risk patients. Protamine was given. Normothermia was maintained with sterile warm blanket throughout the procedure. The intramyocardial cell injections were performed after protamine was given.
Patient follow-up and event assessment
Patients were scheduled for follow-up at 1 month, 3 months, 6 months, and 1 year in the first year, then every 6 months after. Patients were followed for an average of 21.6 months (SD 16.8, maximum 68.9) to determine events. A total of 3,094.9 person-months contributed to the study. Deaths were determined by telephone/e-mail survey and hospital records.
Statistics
Statistical analyses were carried out with SPSS TM for Windows version 10.0 (SPSS Inc, Chicago, IL) and STATA for Windows version 11.0 (StataCorp LP,Texas, TX). Continuous variables are expressed as the mean ± SD unless otherwise indicated. The categorical data was reported as proportion. Paired t-test was used to compare the mean difference of NYHA class, LVEF and scores of quality of life between pre and post treatments. Independent sample t-test was used to compare the mean difference of the LVEF between patients who underwent OPCAB plus intramyocardial cell injection and patients who underwent intramyocardial injection alone.
Probability of freedom of event (death) was calculated according to the Kaplan-Meier survival estimates and measured from the date of surgery to the event (death). Differences between pairs of actuarial curves were tested by log-rank test regarding survival estimates. Cox regression analysis was performed on patients' baseline characteristics (age, gender, diagnosis, diabetes, hypertension, hypercholesterolemia, pulmonary hypertension, renal failure, NYHA class, serum creatinine, preop LVEF, type of operations and number of ACPs) to investigate, and confirm the associations of different variables determined by univariate analysis, also to identify predictors of mortality after cell injection. Multivariate Cox regression analysis was also performed to determine hazard ratios (HRs) and 95% confidence intervals corrected for confounding factors. A p value of less than 0.05 was considered significant.
Results
Early Clinical Outcome
There was no new ventricular arrhythmia during hospital admission (median = 8 days, range 3-198 days). Thirty-day mortality rate was 3.3% (2/60) for DCM and 8.4% 
Survival Analysis
Total follow-up time was 3,094.9 patient-months. Total mortality was 45 of 143 patients (31.5%) during follow-up period, resulting in 14.5 per 1000 patient-months (95%CI: 10.6-19.5) of overall mortality rate. Thirty-six of 132 patients (27.3%) died during follow-up after 30-days. The mortality rate for those surviving the first month was 11.6 per 1000 patient-years (95%CI: 8.2-16.1).
One DCM patients underwent heart transplantation. Overall cardiac death was 43 of 45 patients. Cardiac death included all patients with cardiac-related deaths (28/45, 62.2%) or deaths of unknown causes (17/45, 37.8%). Two patients died of cancer at 599 days and 1,177 days after cell injection.
Overall survival probability at 12, 24, 36 and 48 months after treatments were 79.9% (95%CI: 72.1-85. Factors associated all-cause mortality -Kaplan Meier Estimates Survival: For overall patients, the following variables were associated with all-cause mortality after cell injection: age (p = 0.03), renal failure (p = 0.02), NYHA class (p = 0.004) and preop LVEF (p < 0.001, Figure 4B ). There was no statistically significant difference of survival after the cell injection between ICM and DCM (p = 0.93, Figure 4C ). Subgroup analysis showed hypercholesterolemia (p = 0.02) and preop LVEF (p = 0.003) were significant associated with all-cause mortality in DCM and renal failure (p = 0.02), NYHA class (p = 0.001), preop LVEF (p = 0.008) were significant associated with all-cause mortality in ICM. There was no statistically significant difference of survival after the cell injection between patients who underwent cell injection alone and patient who underwent OPCAB plus cell injection (p = 0.5, Figure 4D ).
Risk Predictors for all-cause mortality -Cox proportional hazard model: Cox regression analyses suggested that only preop LVEF (hazard ratio 0.91, 95%CI 0.87-0.95, p < 0.001) was associated with decreased survival.
Discussion
This study demonstrates the safety of intramyocardial peripheral blood stem cell transplantation in patients with DCM and ICM. The 30-day mortality was about 6%. With increasing clinical experience, mortality could be lowered in both groups. The efficacy of the cell injections was demonstrated, comparing postoperative and preoperative NYHA functional class, LVEF 
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and quality of life. NYHA functional class, LVEF and half of the domains in quality of life questionnaire were significantly improved in both DCM and ICM.
In summary, survival after intramyocardial cell injection was 79.9% after 1 year, 67.9% after 2 years, 62.9% after 3 years, and 55.4% after 4 years ( Figure 4A ). Only preop LVEF (hazard ratio 0.91, 95%CI 0.87-0.95, p < 0.001) was associated with decreased survival. Patients with LVEF over 25% had a better survival. In comparison to studies on other heart failure treatments, (including medical treatments, Cardiac resynchronization therapy, devices for ventricular reshaping, surgical ventricular restoration, ventricular assisted devices and heart transplantation), survival was slightly better in the early phase about 1 year after cell injection. Survival after cell injection was better than for patients awaiting heart transplantation or those without AICD/ CRTD implantation ( Figure 5 ).
8-11
Among available medical therapies, the addition of a β-blocker to conventional therapy was associated with a significant impact on morbidity and mortality. Angiotensin receptor blockers (ARB) are superior to angiotensin-converting enzyme inhibitors (ACEI) in reducing all-cause mortality or hospitalization in treatment of heart failure. Aldosterone blockers effectively reduces mortality in patients treated with an ACEI/ ARB and a beta blocker in the patients with acute myocardial infarction and chronic heart failure.
12 Digoxin is beneficial in terms of reduction of hospitalization in patients who had lower LVEF and systolic blood pressure, higher prevalence of males, third heart sound and peripheral edema.
Except for heart transplantation, all other available treatments mostly treat the end results of the pathological changes in heart failure and do not take care of the causes (cardiomyocytes). The advances made in transplant candidate management, selection, surgical techniques, immunosuppression and post-transplant patient care have resulted in significant improvements in patient outcomes. The mortality rate was 12% at 30 days (95%CI: 11-13%) and 19% at 1 year (95%CI: 17-21%) after heart transplantation. Survival after 5 years was 71% (95%CI: 68-73%) and after 10 years was 56% (95%CI: 53-59%).
14 However the shortage of donor hearts remains problematic, especially in elderly ICM patients who may have increased risk for immunosuppression related complications like, renal failure or malignancy. 15 However, there is a high risk of death while awaiting transplantation.
Research results on outcomes of stem cell injection for DCM were limited. Vrtovec B., et al., 16 investigated the effects of intracoronary transplantation of CD34 + cells in patients with DCM. Twenty eight patients were randomized to have intracoronary peripheral blood CD34 + cells injection which were mobilized by granulocyte-colony stimulating factor and collected via apheresis compared with control. At 1 year, intracoronary peripheral blood CD34 + cells injection was associated with an increase in LVEF (from 25.5 ± 7.5% to 30.1 ± 6.7%; p = 0.03), an increase in 6-minute walk distance and a decrease in NT-proBNP. The 1-year mortality or heart transplantation was lower in patients receiving cell injection (2/28, 7%) than in controls (8/27, 30%) (p = 0.03).
Stem cells for treatment of myocardial infarction and ICM that are under-investigated clinically are mainly hematopoietic stem cells. Bone-marrow or peripheral blood derived stem cells have however shown positive in other clinical trials in both acute and chronic myocardial ischemia/ infarction.
17-19
LVEF improvement ranged from 2.5-15 percentage points. There have also been negative studies in terms of LVEF.
20
The reasons for the disparity in results may be due to the differences in types of cells, e.g. CD34 + , CD 133 + or unselected bone-marrow stem cells, dosage of cells, type of patients (acute or chronic myocardial ischemia) and delivery methods. Largescale human clinical trials are underway in which subpopulations of autologous bone marrow-derived cells are re-administered into myocardial infarction patients. In the REPAIR-AMI trial, parameters such as infarct size and LVEF were modestly, yet significantly improved. Combined end point of death, myocardial infarction and necessity for revascularization, was significantly reduced in the cell group two years after intracoronary administration. 21 Akar et al., 22 evaluated the long-term safety and efficacy of autologous bone marrow mononuclear cell implantation in patients with ICM (who have at least one ischemic area that cannot be re-vascularized by conventional methods) compared with case match-controls who underwent incomplete revascularization by CABG. Bone marrow cells were aspirated from the iliac crest, were processed on the COBE Spectra (Gambro BCT, Lakewood, CO, USA). Final bone marrow cell preparation (57.5 ± 8.9 ml) contained a mean of 31.9 ± 4.4 × 10 6 (range 0.05-80.4 × 10 6 ) CD34+ cells. Cells were injected at the ischaemic (viable infarct border zone) and ungraftable area in combination with coronary artery bypass grafting. They found that cell injection improved perfusion and LVEF in the treatment group. However, Kaplan-Meier survival estimation at 5 years, including in-hospital mortality, was 78.9 ± 10%, in the cell group versus 71.1 ± 11% for controls (p = 0.48). Event-free survival (cardiac events) including mortality was also similar between the two groups (29.6 ± 13.1% vs 17.1 ± 14.4%; p = 0.99).
Yousef et al.,
23 presented the first 5-year follow-up of intracoronary autologous bone marrow mononuclear cell infusion after acute myocardial infarction. An equal number of myocardial infarction patients who were offered the procedure but declined to be control subjects. An early significant improvement in LVEF 3 months and 1 year was followed at 5 years by greater exercise capacity and lower mortality (1 death vs. 7 deaths) in the treated patients.
In this current study, the reasons we delivered the cells by direct intramyocardial injection are: (1) intramyocardial injection is a simple method, (2) the target area of injection can be seen directly, (3) cell retention after implantation is maximized compared with trans-catheter coronary artery infusion or retrograde coronary venous infusion, and (4) do not effect coronary stents. The advantages of using autologous peripheral blood derived stem cells in our study are as follows as autologous cells (1) create no immunologic concern, (2) are easily harvested via blood donation, (3) have no systemic effect during the blood collection for progenitor cell selection and expansion, (4) the cell populations harvested are not in the early phase of development, thus there are no tumor formation issues, and (5) ability of repeated procedure. However, the disadvantages are: (1) the cells may not be as potent as other embryonic or pluripotent stem cells to repair all the damaged areas, (2) cells had limited self-renewal process, therefore the improvement may not last forever, and (3) patients with blood-borne infections such as hepatitis or patients with chronic immunosuppressant could not be treated.
The proposed mechanisms of intramyocardial ACPs injection are paracrine effect, homing signal and possible transdifferentiation of ACPs to cardiomyocytes. Proving this in clinical trials has been difficult, although it is supported by basic science research.
Although this study was a non-randomized study, it did include all spectrums of the common types of heart failure patients. The data were prospectively collected and followed-up. We do not have control group in this analysis. However, we have reported our case-match studies for both DCM and ICM previously. Those patients who had undergone intramyocardial ACPs injection tended to have improvement in NYHA functional class and LVEF than in the controls. 24, 25 The future researches areas are many: (1) the explorations of new types of cells, e.g. resident cardiac progenitor cell, umbilical cord blood stem cells, induced pluripotent stem cells or combined stem cells, (2) creation of a receptive cell environment, (3) timing of stem cell therapy, (4) non-invasive in vivo cell tracking, (5) pharmacologic manipulation or combined gene therapy, (6) repeated cell injections and (7) heart tissue engineering.
Limitation of the study
This is not a randomized study. Some patients came from overseas; therefore they could not come for follow-up echocardiogram or cardiac MRI. However, we were able to obtain echocardiogram, NYHA functional class results and quality of life questionnaires from them. Follow-up LVEF was only corrected in 41.3% of the patients and 73% of them was measured by echocardiogram. Assessment of LVEF was performed locally by investigators without involvement of a central core laboratory. As such, it is possible that for each assessment, a different technique may have been used. It is possible that LVEF estimates were originally reported as ranges from echocardiographic assessment and converted to a single number for the purpose of study entry. However, the status of follow-up patients was obtainable for survival analysis.
Conclusions
Intramyocardial ACPs injection is feasible and safe in both DCM and ICM. The NYHA, quality of life and LVEF had significantly improved in both DCM and ICM. The early results
